Company Profile

Suvica Inc
Profile last edited on: 11/15/19      CAGE: 62P34      UEI: HUHSLL149YT7

Business Identifier: Discovery and development of small molecules for treatment of cancer
Year Founded
2010
First Award
2013
Latest Award
2019
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

PO Box 3131
Boulder, CO 80307
   (303) 921-6680
   info@suvica.com
   www.suvica.com
Location: Single
Congr. District: 02
County: Boulder

Public Profile

Suvica is a biotechnology company structured around discovery and development of small molecules for cancer treatment. Currently, they have a small molecule protein synthesis inhibitor (SVC112 ) in pre-clinical development for a variety of cancer indications, including head & neck cancer, melanoma, colorectal cancer, and non-small cell lung cancer. With a patent filed for Composition of Matter protection, SVC112 has shown pre-clinical efficacy as monotherapy and in combination with standard therapies such as radiation and newly approved targeted agents. SuviCa Inc. and the University of Colorado have an exclusive license agreement for a CU drug screening technology to identify novel therapies for cancer developed by CU-Boulder Associate Professor Tin Tin Su - CSO and Co-founder of the firm. The underpinning work involves a genetically modified Drosophila fruit fly model to screen for compounds effective against various types of cancer, either alone or in combination with existing therapies. The screening technique will be used to identify new clinical candidates using a methodology that is both time efficient and cost-effective. Because it uses a whole-animal screening model, the technique can more easily eliminate drug candidates with undesired toxicity.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $1,999,990
Project Title: Clonogenic High - Throughput Assay for Screening Radiation Modulation
2017 1 NIH $297,604
Project Title: Clonogenic High Throughput Asssay for Screening Radiation Modulators
2015 2 NIH $1,748,524
Project Title: IGF OT IGF Radiation Modulators for Head and Neck Cancer
2013 1 NIH $249,672
Project Title: Development of Radiation Modulators for Use During Radiotherapy

Key People / Management

  Judy Hemberger -- CEO

  Barbara Frederick

  Huw M Nash -- Chief Operating Officer

  Wendi Pevler -- CFO

  Bert Pronk -- Vice President Clinical Development

  Gijsbertus Pronko

  Tarek Sammakia -- Head Of Chemistry

  Tin Tin Su -- Cso And Co-Founder

  Callie Weiant -- Vp Business Development